Rezultati pretraživanja
  1. 17. ožu 2019.

    Great talk by on value of PSMA-PET in men with hormone-sensitive . Yes we scan! Contrary, limited value yet in . Thank you for highlighting our data

    Prikaži ovu nit
  2. 17. ožu 2019.

    Prof Albers recommends PET in all men with The value of this is not proven. All large CRPC studies to date are based on conventional imaging. PSMA-PET is useful in hormone-sensitive BCR, but men wit high-risk! M0CRPC primarily need treatment, not PET imaging

    Prikaži ovu nit
  3. 31. srp 2019.

    Great news for patients suffering from in the US. This approval marks another important milestone in our fight against . Great to see Bayer Oncology growing. Proud of this terrific accomplishment of our and team. Well done, team!

  4. 17. ožu 2019.
    Odgovor korisnicima

    maybe, but only within in clinical trials and certainly not in men with and short PSA-DT.

  5. 4. lip 2012.

    All about . Tagged on

  6. Fruitful discussion ABOUT . The role of and how to integrate In daily clinical practice. Now on my way back to Spain, tomorrow some work and on Sunday

  7. 22. lis 2018.

    Day 4 of has been a busy one so far! Keep a lookout right here for from Barbara Burtness of on , on , and Simon Crabb of on !

  8. : Bayer receives approval from on new treatment

  9. 3. lip 2019.
    Odgovor korisniku/ci

    This is really interesting, looking forward to the data releases! Here is an article I researched looking at about nmCRPC... straight to the source insights.

  10. 21. lis 2018.

    A massive thanks to for joining us at to give his perspective on treating patients with , full interview here soon!

  11. 20. stu 2018.

    FYI: CME/CNE certified webinar with a great panel. Hope you can make it!

  12. 6. ruj 2019.

    Over 174,000 new cases of prostate cancer will be diagnosed in the U.S. in 2019. This weekend, Bayer is at 's 2019 Patient Conference to discuss a treatment option for .

  13. Join us and this Nov to raise awareness for ! Visit to learn more.

  14. 13. ruj 2018.

    The MW CEPAC will now vote on the comparative clinical effectiveness and overall economic value for antiandrogen therapies for .

  15. 28. sij

    Going to ? Join us in on Saturday, 21 March for our "Defining a Patient-Centred Approach to Non-Metastatic Castration-Resistant Prostate Cancer" symposium. Learn more and register at

  16. 31. sij

    : New treatment for men with from receives positive opinion

  17. 29. sij

    Darolutamide: Approved For . article by Neal Shore, MD, FACS on the evolving treatment landscape, preclinical and clinical data on darolutamide, and ongoing considerations for treating pts with nmCRPC on UroToday >

  18. 15. ruj 2018.
  19. 4. lip 2018.

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.